- Long acting cabotegravir (CAB-LA) is a two-monthly jab that can prevent HIV infections through sex. It virtually nullifies people’s chances of contracting the virus and it’s more effective than the daily prevention pill that’s currently available in South Africa.
- Who is this injection for? Anyone who’s worried about contracting HIV. But young African women (among whom new infections are highest) stand to benefit the most because the jab eliminates the stress of taking a pill every day.
- For this World Aids Day edition of Bhekisisa’s television show Health Beat, we speak to CAB-LA’s manufacturer (ViiV Healthcare), the scientists who’ve been testing it and the first women in the country to use the jab.
Mohale Moloi worked at Bhekisisa as a television producer and health journalist from July 2021 to March 2024.
Yolanda Mdzeke was a junior multimedia reporter and multimedia reporter at Bhekisisa between March 2021 and June 2025.
Jessica Pitchford is Bhekisisa's TV and multimedia editor. She's been a journalist since the early nineties and has reported on some pivotal events in South Africa’s political history, such as the country’s transition to democracy and the work of the Truth & Reconciliation Commission.
Mia Malan is the founder and editor-in-chief of Bhekisisa. She has worked in newsrooms in Johannesburg, Nairobi and Washington, DC, winning more than 30 awards for her radio, print and television work.
Ntuthuko “Lolly” Gumbi-Fakude is a freelance video editor. She has almost 20 years experience in the news and broadcast media industry on projects like the coronation of King Misuzulu Zulu.
